Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Kinney

Showing results (261-270 of 272) with videos related to

Pageof 28
Sort By:
Bioorganic & Medicinal Chemistry|August 23, 2005
Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonistsAlexey B Dyatkin, Yong Gong, Tamara A Miskowski, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrinsBart L De Corte, William A Kinney, Li Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 18, 2007
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic ratsRosemary J Santulli, William A Kinney, Shyamali Ghosh, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonistsAlexey B Dyatkin, William J Hoekstra, William A Kinney, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2004
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailabilityShyamali Ghosh, Rosemary J Santulli, William A Kinney, et al.
Experimental Hematology|September 16, 2025
A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCsAshlee J Conway, Tolulope O Rosanwo, Thomas E Williamson, et al.
Blood|January 12, 2026
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemiaJanet L Kwiatkowski, Alexis A Thompson, Jennifer Schneiderman, et al.
Current Environmental Health Reports|July 21, 2016
The Microbiota, Immunoregulation, and Mental Health: Implications for Public HealthChristopher A Lowry, David G Smith, Philip H Siebler, et al.
Science Translational Medicine|February 10, 2017
Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitorsSergei Doulatov, Linda T Vo, Elizabeth R Macari, et al.
The New England Journal of Medicine|October 9, 2024
Hematologic Cancer after Gene Therapy for Cerebral AdrenoleukodystrophyChristine N Duncan, Jacob R Bledsoe, Bartosz Grzywacz, et al.
Pageof 28

Showing results (261-270 of 272) with videos related to

Sort By:
Pageof 28
Bioorganic & Medicinal Chemistry|August 23, 2005
Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonistsAlexey B Dyatkin, Yong Gong, Tamara A Miskowski, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrinsBart L De Corte, William A Kinney, Li Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 18, 2007
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic ratsRosemary J Santulli, William A Kinney, Shyamali Ghosh, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2004
Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonistsAlexey B Dyatkin, William J Hoekstra, William A Kinney, et al.
Bioorganic & Medicinal Chemistry Letters|October 27, 2004
1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailabilityShyamali Ghosh, Rosemary J Santulli, William A Kinney, et al.
Experimental Hematology|September 16, 2025
A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCsAshlee J Conway, Tolulope O Rosanwo, Thomas E Williamson, et al.
Blood|January 12, 2026
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemiaJanet L Kwiatkowski, Alexis A Thompson, Jennifer Schneiderman, et al.
Current Environmental Health Reports|July 21, 2016
The Microbiota, Immunoregulation, and Mental Health: Implications for Public HealthChristopher A Lowry, David G Smith, Philip H Siebler, et al.
Science Translational Medicine|February 10, 2017
Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitorsSergei Doulatov, Linda T Vo, Elizabeth R Macari, et al.
The New England Journal of Medicine|October 9, 2024
Hematologic Cancer after Gene Therapy for Cerebral AdrenoleukodystrophyChristine N Duncan, Jacob R Bledsoe, Bartosz Grzywacz, et al.
Pageof 28